Related Experiment Video

Updated: Jul 16, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology

Kapila Ratnam1, Jennifer A Low

  • 1PSI International, Inc., USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|March 3, 2007
PubMed

Insights

Poly(ADP-ribose) polymerase (PARP) inhibitors show promise in cancer therapy by enhancing DNA-damaging treatments and targeting tumors with repair defects. Clinical trials are underway to evaluate their efficacy and challenges.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Poly(ADP-ribose) polymerase (PARP) is a key nuclear enzyme involved in DNA repair.
  • PARP activation signals DNA damage by adding ADP-ribose units to cellular components.
  • PARP is increasingly recognized as a significant therapeutic target, particularly in cancer treatment.

Purpose of the Study:

  • To review the preclinical and clinical data of PARP inhibitors in cancer therapy.
  • To discuss the potential of PARP inhibition in enhancing conventional cancer treatments.
  • To highlight challenges in the clinical development of PARP inhibitors.

Main Methods:

  • Review of preclinical (in vitro and in vivo) and clinical trial data for PARP inhibitors.
  • Analysis of PARP inhibitor efficacy in combination with DNA-damaging agents.
  • Examination of tumor sensitivity to PARP inhibition, especially in BRCA-mutated cancers.

Main Results:

  • PARP inhibition potentiates the activity of DNA-damaging agents like alkylators, platinums, and radiation.
  • Tumors with DNA repair defects, such as BRCA mutations, exhibit heightened sensitivity to PARP inhibitors.
  • Multiple companies have initiated oncology clinical trials (Phase 0-2) for PARP inhibitors.

Conclusions:

  • PARP inhibitors represent a promising therapeutic strategy in oncology.
  • Combination therapies involving PARP inhibitors and DNA-damaging agents show significant potential.
  • Further research is needed to address challenges in the clinical development and application of PARP inhibitors.

More Related Videos

Adapting 3' Rapid Amplification of CDNA Ends to Map Transcripts in Cancer09:38

Adapting 3' Rapid Amplification of CDNA Ends to Map Transcripts in Cancer

Published on: March 28, 2018

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...